Venture Capital

Medincell's latest results show a planned loss but reveal a strategic shift to recurring royalties, fueled by UZEDY®'s success and a pipeline set for growth.

A forgotten corner of oncology is set for a 14.2% CAGR. A new wave of drugs for chemo-induced neuropathy signals a major market realignment.

A new transatlantic force in financial services M&A is born as UK's Fenchurch merges with US fintech specialist Broadhaven, creating a 110-banker powerhouse.

With a novel non-hallucinogenic drug, Enveric Biosciences heads to the BIO convention seeking partners. Can its unique science secure its future?

With the hire of Patrick Duffy, Dropzone AI signals a major push in its mission to solve cybersecurity's twin crises with a new breed of AI agents.

With veteran investor Travis Read as new President & COO, AmMax Bio signals a major push to accelerate its promising antibody-drug conjugate pipeline.

Oxford Financial Group's major Cincinnati expansion highlights a national trend: the strategic battle for top talent and regional dominance in wealth management.

Adial Pharmaceuticals pivots from addiction to inflammation, securing $32M and poaching Azora's leadership to drive its new ulcerative colitis drug, AT177.

New research reveals a stark divide: leaders prioritize R&D while the public and investors demand reinvestment in workers. Who will win the battle for AI's gains?

Tiny biotech HCW Biologics reports promising early data for its alopecia drug. But with a small sample size and big pharma rivals, is this a true breakthrough?

With $10M in funding, Magnitude launches an autonomous AI workforce to combat machine-speed threats, forcing a reckoning in third-party risk management.

With a major debt financing, French biotech Inventiva is funded through a pivotal Phase 3 trial for its MASH drug, highlighting a strategic shift in biotech funding.

With a historic $1.1B in funding, David Silver's Ineffable Intelligence partners with Google Cloud to build an AI that learns from experience, not just data.

Univest Securities secures $8M for Pop Culture Group via a direct offering. We look under the hood at the deal's mechanics and CPOP's ambitious growth plans.

Great Estate Blockchain divests its main revenue source after a flawed deal structure implodes, leaving the penny-stock firm seeking a new identity.

Adaptive Biotechnologies' new debt offering is more than a financial tune-up; it's a calculated move to sever a costly royalty deal and arm its star MRD division for a separate future.

AIRA ushers in new leadership with Boris Steffen as President, poised to navigate economic turbulence and shape the future of the insolvency profession.

With a new $75M fund, Gutter Capital is doubling down on its 'old school' model: intense operational support for 'overlooked' founders in New York City.

After a $40 billion market collapse, venture capital is back with a new playbook. Anterra Capital’s new fund signals a shift from hype to real-world AI.

Amid a venture capital slowdown, a Philadelphia model is gaining traction by prioritizing discipline over hype. We explore how this ecosystem is making startups investor-ready.